Company Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients.
The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma.
It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma.
The company was founded in 2014 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 1947 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 152 |
| CEO | Chen Schor |
Contact Details
Address: 131 Dartmouth Street, 3rd Floor Boston, Massachusetts 02116 United States | |
| Phone | 650 503 9095 |
| Website | adicetbio.com |
Stock Details
| Ticker Symbol | ACET |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000002034 |
| CUSIP Number | 007002108 |
| ISIN Number | US0070021086 |
| Employer ID | 11-1720520 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Chen Schor BA, CPA, M.B.A. | Chief Executive Officer, President and Director |
| Dr. Aya Jakobovits Ph.D. | Founder and Independent Director |
| Brian Nicholas Harvey | Chief Financial Officer |
| Dr. Blake Aftab Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Donald Healey Ph.D. | Chief Technology Officer |
| Amy Locke | Chief Human Resource Officer |
| Dr. Julie Maltzman M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 1, 2019 | 15-12G | Securities registration termination |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 1, 2019 | 8-K | Current Report |
| Sep 20, 2019 | 8-K | Current Report |
| Aug 26, 2019 | 8-K | Current Report |